1-8 of 8
Daiju Ichikawa
Close
Sort by
Journal Articles

Elucidation of the IMiDs-Resistant Mechanism and Development of the Overcoming Drugs Inducing CRBN Independent G2/M Cell Cycle Arrest in Myeloma Cells

Ryo Uozaki, Shuji Aida, Takasi Yamagughi, Tomofumi Yamamoto, BPharm, Sho Kashiwazaki, Hiroshi Yanagawa, Daiju Ichikawa, Maiko Matsushita, Yutaka Hattori
Journal: Blood
Blood (2018) 132 (Supplement 1): 4451.
https://doi.org/10.1182/blood-2018-99-115909
Published: 2018
Journal Articles

Immunomodulatory Effects of Proteasome Inhibitors in Multiple Myeloma

Sho Kashiwazaki, Satoshi Kamiko, Ryo Uozaki, Tomofumi Yamamoto, BPharm, Daiju Ichikawa, Yutaka Hattori, Maiko Matsushita, Maki Hirao, Hisako Kunieda, Kohei Yamazaki
Journal: Blood
Blood (2018) 132 (Supplement 1): 1946.
https://doi.org/10.1182/blood-2018-99-115894
Published: 2018
Journal Articles

A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon

Misa Nakamura, Daiju Ichikawa, PhD, Shuji Aida, Nahoko Hashimoto, Wakana Murota, Ryo Uozaki, Mikio Okayama, MD, Kota Fujimori, Yuko Yonemura, Noriko Tabata, PhD, Hiroshi Yanagawa, PhD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5377.
https://doi.org/10.1182/blood.V130.Suppl_1.5377.5377
Published: 2017
Journal Articles

10 Years History of Cost-Effectiveness for 209 Newly Diagnosed Multiple Myeloma Patients at a Single-Institute in Japan

Kenshi Suzuki, MD PhD, Tomofumi Yamamoto, Masahiro Ikeda, MD, Tomomi Takei, MD, Nobuhiro Tsukada, MD PhD, Tadao Ishida, MD PhD, Arimi Ueda, Daiju Ichikawa, PhD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5620.
https://doi.org/10.1182/blood.V128.22.5620.5620
Published: 2016
Journal Articles

Komaroviquinone-Derivatives, Revealed Anti-Tumor Effect on High-Risk Multiple Myeloma Cells In Vitro as Well as In Vivo

Mariko Sato, Kota Fujimori, Shotaro Kitabatake, Mikio Okayama, MD, Daiju Ichikawa, PhD, Yutaka Suto, PhD, Genji Iwasaki, PhD, Fumiyuki Kiuchi, PhD, Takashi Yamaguchi, Arimi Ueda, Shuji Aida, Hitomi Nakayama, MD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2100.
https://doi.org/10.1182/blood.V128.22.2100.2100
Published: 2016
Journal Articles

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Masashi Hozumi, Daiju Ichikawa, PhD, Maiko Matsushita, MD PhD, Eriko Kamiyama, Hiroshi Yanagawa, PhD, Noriko Tabata, PhD, Shotaro Kitabatake, Arimi Ueda, Takashi Yamaguchi, Mariko Sato, Yutaka Hattori, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1800.
https://doi.org/10.1182/blood.V126.23.1800.1800
Published: 2015
Journal Articles

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

Yutaka Hattori, MD PhD, Maiko Matsushita, MD PhD, Noriko Tabata, Hirokazu Shiheido, Hiroshi Yanagawa, PhD, Arimi Ueda, Masashi Hozumi, Shotaro Kitabatake, Daiju Ichikawa
Journal: Blood
Blood (2014) 124 (21): 5718.
https://doi.org/10.1182/blood.V124.21.5718.5718
Published: 2014
Journal Articles

Codon 72 Polymorphism Of TP53 Gene Is a Novel Prognostic Marker For Thalidomide Therapy In Multiple Myeloma

Yutaka Hattori, MD, PhD, Yurika Ikeda, Yuya Suzuki, Daiju Ichikawa, PhD, Maiko Matsushita, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1891.
https://doi.org/10.1182/blood.V122.21.1891.1891
Published: 2013